<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877223</url>
  </required_header>
  <id_info>
    <org_study_id>2020-006-MucOs</org_study_id>
    <nct_id>NCT04877223</nct_id>
  </id_info>
  <brief_title>Monocytes as Predictors of Cystic Fibrosis-related Bone Disease</brief_title>
  <acronym>MucOs</acronym>
  <official_title>Study of Blood Monocytes as a Predictive Marker of Cystic Fibrosis-related Bone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Reims Champagne-Ardenne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Reims Champagne-Ardenne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Circulating monocytes RANK and MCSF-R expression is predictive of Cystic&#xD;
      Fibrosis-related Bone Disease.&#xD;
&#xD;
      Study design: Single-center comparative cross-sectional study Population: Patients with a&#xD;
      CFTR channel mutation causing cystic fibrosis consulting the Centre de Ressources et de&#xD;
      Compétences de la Mucoviscidose (CRCM) at Reims University Hospital will be recruited.&#xD;
      Healthy controls will be recruited from donors at the Etablissement Français du Sang Grand&#xD;
      Est, Reims.&#xD;
&#xD;
      Judgment criteria:&#xD;
&#xD;
      - Main judgment criterion: X Expression level of CD115 (MCSF receptor) and CD265 (RANK)&#xD;
      evaluated by flow cytometry receptors on the membranes of circulating monocytes.&#xD;
&#xD;
      - Secondary judgment criteria: X Rate of circulating CD115 +, CD265 +, CD115 + / CD265 +&#xD;
      monocytes X Number of multinucleated cells with more than 2 nuclei and with an actin ring&#xD;
      observed under fluorescence microscopy after osteoclastic differentiation X Surface of dentin&#xD;
      resorbed in vitro by osteoclasts during an osteoclastic functionality test on dentin X Serum&#xD;
      S1P levels assayed by ELISA technique.&#xD;
&#xD;
      Investigation plan:&#xD;
&#xD;
      Any eligible patient will be offered to participate in the study during the consultation at&#xD;
      the CRCM. If the patient agrees to participate in the study, he/she will be included.&#xD;
      Participation in the study will not affect its coverage. Participation will lead to the&#xD;
      collection of three tubes of whole blood additional to those used as part of usual care, as&#xD;
      well as the collection of demographic data (age, sex, height, weight, body mass index),&#xD;
      sports practice, clinical images and interpretation, medical history (diabetes, infectious&#xD;
      status, bone metabolism disorders, drug treatments followed, psychiatric disorders). Any&#xD;
      subsequent donor from the EFS GE collected under the ALC / PIL / DIR / AJR / FO / 606&#xD;
      agreement and presenting characteristics of age +/- 2 years and identical gender will then be&#xD;
      included.&#xD;
&#xD;
      Statistical analysis plan:&#xD;
&#xD;
      Qualitative variables will be described in terms of number and percentage. The quantitative&#xD;
      distribution variables according to the Normal law will be described in the form of mean +/-&#xD;
      standard deviation or in the form of boxplots (median, quartiles, deciles) if a distribution&#xD;
      not following the Normal law is observed. ANOVA test, non-parametric Wilcoxon signed-rank&#xD;
      test or chi² test will be aplied depending on the application conditions. A value of p &lt;0.05&#xD;
      will be considered statistically significant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of CD115 and CD265 expression on circulating monocytes</measure>
    <time_frame>Immediately after sampling</time_frame>
    <description>Flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of CD115+, CD265+ and CD115+/CD265+ cells</measure>
    <time_frame>Immediately after sampling</time_frame>
    <description>Flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of multinucleated cells with actin ring</measure>
    <time_frame>3 weeks after sampling</time_frame>
    <description>Phalloïdin/DAPI staining and microscope observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of resorbed dentin surface</measure>
    <time_frame>3 weeks after sampling</time_frame>
    <description>Scanning electron microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum S1P concentration</measure>
    <time_frame>Immediately after sampling</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF</arm_group_label>
    <description>Patients with Cystic Fibrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>CF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic fibrosis patients consulting the CRCM of Reims University Hospital. Healthy controls&#xD;
        from Etablissement Français du Sang Grand Est, Reims&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 20 and 65 years (+/- 2 years)&#xD;
&#xD;
          -  Patients of the CRCM of Reims University Hospital&#xD;
&#xD;
          -  Patients with at least one CF causing mutation in CFTR gene&#xD;
&#xD;
          -  Patients agreeing to participate in the study (informed consent form)&#xD;
&#xD;
          -  Patients fluent in French&#xD;
&#xD;
          -  Patients affiliated with a social security regimen&#xD;
&#xD;
          -  Healthy donors between 20 and 65 years (+/- 2 years)&#xD;
&#xD;
          -  Healthy donors giving blood at EFS GE, Reims&#xD;
&#xD;
          -  Healthy donors agreeing to participate in the study (informed consent form)&#xD;
&#xD;
          -  Healthy donors fluent in French&#xD;
&#xD;
          -  Healthy donors affiliated with a social security regimen&#xD;
&#xD;
          -  Healthy donors whose characteristics agree with the ALC/PIL/DIR/AJR /FO/606 convention&#xD;
             between EFS GE, Reims, and Reims Champagne-Ardenne University&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having a medical history that may compromise the protocol (psychiatric,&#xD;
             medical or pharmacological disorders such as the use of anti-inflammatory drugs, or&#xD;
             any compound that may alter or modify the inflammatory reaction in the week preceding&#xD;
             the protocol).&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patient with eating disorders (anorexia, bulimia, overeating)&#xD;
&#xD;
          -  Patient protected by law (guardianship, curatorship, hospitalized without their&#xD;
             consent and not protected by law, deprived of liberty)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno RAVONINJATOVO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Ressources et de Compétences de la Mucoviscidose</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno RAVONINJATOVO</last_name>
    <phone>03 26 78 38 68</phone>
    <email>bravoninjatovo@chu-reims.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric VELARD</last_name>
    <phone>03 26 91 80 10</phone>
    <email>frederic.velard@univ-reims.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université de Reims Champagne-Ardenne</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric VELARD</last_name>
      <phone>03 26 91 80 10</phone>
      <email>frederic.velard@univ-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Bone disease</keyword>
  <keyword>Monocytes</keyword>
  <keyword>RANK</keyword>
  <keyword>MCSF-R</keyword>
  <keyword>Osteoclast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

